GlassScriptPhysician profile
Marcos Cintron
NPI 1366593782
$10,068.56
in general payments reported to CMS, 2019-2025
20 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $307 · 2021: $11.10 · 2022: $1,174 · 2023: $2,504 · 2024: $2,309 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,105.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,707.63 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,321.03 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,232.27 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,025.91 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $929.15 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Abbvie INC. | $767.04 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $648.95 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $497.46 | 2024-2025 | Cobenfy |
| Indivior INC. | $373.05 | 2019-2025 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $364.98 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $268.56 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $210.08 | 2019-2020 | |
| Axsome Therapeutics, INC. | $189.20 | 2023-2025 | Auvelity |
| Shire North American Group INC | $172.76 | 2019 | |
| Lundbeck LLC | $157.72 | 2019-2025 | Abilify Maintena, Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $71.20 | 2025 | Erzofri Extended-Release |
| Acadia Pharmaceuticals INC | $44.23 | 2023-2024 | Nuplazid |
| Janssen Scientific Affairs, LLC | $42.35 | 2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $24.32 | 2019 | |
| Almatica Pharma LLC | $20.67 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Cintron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.